NHS Introduces New MS Walking Treatment: How Fampridine Could Transform Mobility for Thousands

New NHS Drug Offers Fresh Hope for People Living With Multiple Sclerosis

Thousands of people living with multiple sclerosis (MS) in England are set to benefit from a newly available NHS treatment designed to improve walking ability. The twice-daily medication, known as fampridine, has been described as a potentially life-changing development because it is the first licensed medicine specifically aimed at helping people with MS overcome walking difficulties.

Multiple sclerosis is a long-term autoimmune condition that affects the central nervous system, including the brain and spinal cord. The disease occurs when the immune system mistakenly attacks the protective covering around nerves, disrupting communication between the brain and the rest of the body.

For many people with MS, mobility problems are among the most challenging symptoms. Difficulty walking can affect independence, confidence, employment, and everyday activities. Until now, many patients have depended mainly on physiotherapy, mobility equipment, walking aids, and supportive treatments to manage these challenges.

The introduction of fampridine through the NHS marks an important step forward in MS care, offering a new option for eligible patients who experience reduced walking ability.

How Fampridine Works to Improve Walking Ability

Fampridine, also known by the brand name Fampyra, works by improving the way electrical signals travel through damaged nerves. MS can interrupt nerve communication, making it harder for the brain to send clear messages to muscles.

The medication acts as a signal booster, helping damaged nerves transmit messages more effectively. By improving nerve signalling, fampridine may help some people with MS move more easily, increase walking speed, and maintain mobility for longer periods.

The treatment does not cure multiple sclerosis or reverse nerve damage caused by the condition. However, for certain patients, even a small improvement in movement can have a major impact on daily life.

Being able to walk more confidently around the home, visit friends, continue working, or complete everyday tasks independently can significantly improve quality of life.

Who Will Be Eligible for the New NHS Treatment?

Health officials estimate that around 5,000 people with MS could benefit from fampridine during the first year of NHS availability in England.

The treatment will be offered to patients who meet specific medical criteria based on their level of disability. Doctors use a measurement system called the Expanded Disability Status Scale (EDSS) to assess how MS affects mobility and overall function.

Patients with EDSS scores between four and seven may be considered for treatment. This includes people who can still walk independently but may struggle with distance, as well as those who require mobility support.

Before continuing with the medication, patients will usually undergo a short trial period lasting between two and four weeks. Healthcare professionals will assess walking ability before and after starting treatment.

Those who show measurable improvement will be able to continue taking fampridine with regular medical reviews.

Clinical Evidence Shows Benefits for Some MS Patients

Research into fampridine has shown promising results. Clinical trials found that the medication improved walking speed in a significant proportion of participants, with around 43 per cent of patients showing measurable improvements.

Some patients also reported being able to walk for longer periods and complete activities that had previously become difficult.

However, results can vary from person to person. While some individuals experience noticeable improvements, others may see limited benefits. Doctors will therefore monitor each patient carefully to determine whether continuing treatment is suitable.

The availability of fampridine through the NHS means more people will now have access to a treatment that was previously difficult to afford privately.

Patients Welcome Greater Access to MS Medication

For some people with MS, the cost of privately funding fampridine has been a major barrier.

One patient, 65-year-old Aysen Slack from Eastbourne, previously paid for the medication herself but had to stop because of the expense. She said the treatment had appeared to improve her mobility but became financially impossible to continue.

With NHS access now available, patients like Slack hope they can restart treatment and regain some independence.

Mobility changes can have a significant emotional impact on people living with MS. Losing the ability to walk comfortably can affect social activities, mental wellbeing, and confidence. A treatment that helps improve movement may provide benefits beyond physical ability.

MS Organisations Welcome NHS Approval

The MS Society has welcomed the introduction of fampridine, highlighting the potential impact it could have for thousands of people living with the condition.

More than 120,000 people are estimated to be living with MS in England. While many treatments focus on slowing disease progression or managing symptoms, fampridine provides a specific option for improving walking ability.

Experts have emphasised that healthcare services must have the necessary support and resources to ensure eligible patients across England can access the medication.

Equal access will be important because treatment availability should not depend on where someone lives.

What This Means for the Future of MS Care

The introduction of fampridine represents a positive development in the treatment of multiple sclerosis, particularly for people whose daily lives are affected by mobility problems.

Although the medication is not suitable for everyone with MS, it provides a new opportunity for eligible patients to improve their independence and maintain a more active lifestyle.

For people living with chronic conditions, advances in treatment are not only about extending life but also improving everyday experiences. Being able to walk more easily, participate in activities, and feel more confident can make a meaningful difference.

As NHS services begin offering fampridine more widely, many people with MS will be watching closely to see how the treatment changes mobility support and long-term care.

Conclusion

The NHS rollout of fampridine brings new hope to thousands of people living with multiple sclerosis in England. As the first licensed drug specifically designed to improve walking ability in MS patients, it represents an important milestone in symptom management.

While it will not work for everyone, those who respond positively may experience improvements that make everyday activities easier and help them live more independently.

For many people affected by MS, this new treatment could provide not only better mobility but also renewed confidence and freedom.

Source

The Independent article, published 23 July 2026.

Disclaimer

This article is for informational purposes only and does not replace professional medical advice. Medication decisions should always be made in consultation with qualified healthcare professionals. Eligibility, benefits, and risks of fampridine may vary between individuals. Patients should speak with their MS specialist or healthcare provider before starting any new treatment.